The FDA has approved Takeda’s New Drug Application (NDA) for a combination of pioglitazone HCl (Actos canadian) and glimepiride for the treatment of type-2 diabetes. The combination drug is called Duetact.
Actos directly targets insulin resistance, and glimepiride tablet, a sulfonylurea, acts primarily by increasing the amount of insulin produced by the pancreas.
Duetact will be available in two commonly used dosages of pioglitazone drug/ glimepiride, to be taken once daily: 30 mg/2 mg and 30 mg/4 mg. The medication will be on the market this year.